|
|
|
|
| LEADER |
01621nam a2200325 u 4500 |
| 001 |
EB001999822 |
| 003 |
EBX01000000000000001162723 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Li, Ke Xin
|
| 245 |
0 |
0 |
|a Pharmacogenomic testing in depression
|h Elektronische Ressource
|b a review of clinical effectiveness, cost-effectiveness, and guidelines
|c Ke Xin Li, Hannah Loshak
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, January 31, 2020
|
| 300 |
|
|
|a 1 PDF file (38 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 653 |
|
|
|a Depressive Disorder
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Pharmacogenomic Testing
|
| 653 |
|
|
|a Guidelines as Topic
|
| 700 |
1 |
|
|a Loshak, Hannah
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK562923
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to examine the clinical effectiveness, cost-effectiveness of pharmacogenomic testing versus treatment as usual for treating all severities of diagnosed depression. Additionally, evidence-based guidelines regarding the pharmacogenomic testing in patients with all severities of diagnosed depression will be reviewed
|